Form 4: AC Immune Director Receives Equity Awards

AC Immune SA reports that Director Roy Ervin Twyman was granted restricted stock units and stock options on June 11, 2026.

Summary

• Roy Ervin Twyman, a Director at AC Immune SA, received a grant of 16,568 restricted stock units (RSUs) on June 11, 2026, under the company's 2016 Stock Option and Incentive Plan (SOIP).
• Additionally, on the same date, Twyman was granted options to purchase 38,889 common shares under the SOIP.
• These options have an exercise price of $2.62 per share and are set to fully vest on June 10, 2027.
• Following these transactions, Twyman beneficially owns 92,556 common shares, including 66,556 common shares underlying outstanding RSUs.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents standard director compensation practices and an alignment of interests, but does not contain new operational or financial performance data.

Positives

• Director compensation through equity awards indicates alignment of management interests with shareholder value.
• The grant of RSUs and stock options suggests confidence in the company's future performance and share price appreciation.
• The vesting schedule for stock options encourages long-term commitment from the director.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the granted equity awards is subject to market fluctuations and the company's future stock performance.
• Potential dilution to existing shareholders may occur upon the exercise of stock options and vesting of RSUs.

Future Outlook

The stock options granted to the director are exercisable and will fully vest on June 10, 2027, suggesting an expectation of continued company performance and value appreciation.

Industry Context

StockSavvy.ai notes that the issuance of equity awards to directors is a common practice in the biotechnology and pharmaceutical sectors, aiming to incentivize leadership and align their financial interests with the long-term success of the company, especially given the inherent risks and long development cycles in this industry.

Stakeholder Impact

• Shareholders: The equity awards align director interests with shareholder value, potentially leading to decisions that benefit the company's stock price. However, the exercise of options could lead to minor dilution.

Next Steps

• The stock options granted will vest on June 10, 2027.
• The director's beneficial ownership will be updated as RSUs vest and options are exercised.

Key Dates

Keywords

AC Immune SA, ACIU, Form 4, Director Compensation, Equity Awards, Restricted Stock Units, Stock Options, Beneficial Ownership, Securities Exchange Act